In a 48-year-old man with hypertension, BMI 27, Mallampati II, normal oxygen saturation, who developed difficulty sleeping, daytime sleepiness, and nocturnal dyspnea with choking after moving to high altitude (10,578 ft), which of the following should be recommended now: home sleep apnea test, polysomnography, light therapy, acetazolamide, or zolpidem?

Recommend Acetazolamide Now

You should initiate acetazolamide for this patient with high-altitude central sleep apnea (CSA). This is a classic presentation of altitude-induced CSA at 10,578 feet (>3,200 m), and the most recent 2025 AASM guidelines specifically recommend acetazolamide as first-line treatment for this condition 1.

Clinical Reasoning

Why This is High-Altitude Central Sleep Apnea

This patient's presentation is textbook for altitude-induced CSA:

• Temporal relationship: Symptoms began immediately after relocation to high altitude (10,578 feet/3,223 m)
• Classic symptoms: Nocturnal dyspnea with choking sensation, fragmented sleep with multiple awakenings, daytime fatigue
• No difficulty initiating sleep: Rules out primary insomnia or circadian disorder
• Normal oxygen saturation at rest: 98% on ambient air indicates adequate daytime compensation
• Low pre-test probability for OSA: BMI 27, Mallampati II, no reported snoring, and the choking/dyspnea pattern is more consistent with central events than obstructive events

At altitudes >2,500 m, periodic breathing and CSA develop in nearly all healthy individuals due to hypoxic-induced alterations in chemoreceptor sensitivity and ventilatory control 1.

Why Acetazolamide is the Answer

The 2025 AASM guidelines provide a conditional recommendation for acetazolamide in CSA due to high altitude (very low certainty of evidence) 1. Despite the low certainty rating, the task force emphasized that given the low risk, low cost, and feasibility, acetazolamide is reasonable for symptomatic individuals at altitude 1.

Mechanism: Acetazolamide induces metabolic acidosis through carbonic anhydrase inhibition, which stimulates ventilation and widens the PCO₂ reserve, preventing the development of central apneas during sleep 2. It also lowers blood pressure at altitude, which is beneficial for this hypertensive patient 3, 4.

Evidence of efficacy: Studies demonstrate clinically meaningful improvements in AHI/ODI and sleep architecture after 1-2 nights of treatment with 250 mg acetazolamide 1. The 2018 European cardiology guidelines specifically note that acetazolamide "lowers BP at HA while improving SaO₂ and mountain sickness symptoms" 3.

Dosing: Standard dose is 250 mg twice daily 4, 5.

Why NOT the Other Options

Home sleep apnea test or polysomnography: These are diagnostic tests, not treatments. While they could confirm CSA, the clinical diagnosis is already clear from the history. More importantly, this patient is symptomatic now and needs treatment, not further testing. The guidelines note that CSA at altitude "does not always require intervention" 1, but this patient clearly has significant symptoms affecting quality of life.

Light therapy: This treats circadian rhythm disorders. The patient has no trouble falling asleep and no circadian misalignment symptoms—his problem is sleep fragmentation from respiratory events.

Zolpidem: While the FDA label shows efficacy for transient and chronic insomnia 6, and one review mentions benzodiazepines/zolpidem can "improve sleep without affecting breathing pattern" at altitude 2, this addresses only the symptom (poor sleep) without treating the underlying pathophysiology (periodic breathing/CSA). Zolpidem does not prevent the nocturnal hypoxemia or respiratory events that are causing this patient's symptoms and potentially increasing cardiovascular risk.

Important Caveats

Follow-up Monitoring Required

Monitor electrolytes after 2-4 weeks 1. Acetazolamide can cause hypokalemia and metabolic acidosis, which theoretically could lead to arrhythmias, particularly concerning in this hypertensive patient 1. Also reassess:

• Sleep quality and daytime symptoms
• Blood pressure control (may improve) 3
• AHI if symptoms persist

Common Side Effects

Expect trivial but annoying side effects 1:

• Paresthesias of hands and feet (most common)
• Altered taste (especially carbonated beverages)
• Increased diuresis
• Rarely: kidney stones

Duration of Therapy

The guidelines cannot specify duration because studies only evaluated 1-2 nights 1. However, many individuals acclimate over time with resolution of CSA or symptoms 1. Consider:

• Continuing acetazolamide for at least several weeks
• Reassessing symptoms monthly
• Attempting discontinuation after 2-3 months if symptoms have resolved
• Definitive treatment is descent to lower altitude 1

OSA Consideration

This patient has risk factors for OSA (male, age 48, BMI 27, hypertension). The guidelines note that "OSA is a highly prevalent disease that may also worsen at altitude" 1. If symptoms persist despite acetazolamide, then consider polysomnography to evaluate for coexistent OSA, which may require CPAP in addition to acetazolamide 7.

Blood Pressure Management

Continue his amlodipine. The European guidelines note that calcium channel blockers (like amlodipine) and ACE inhibitors/ARBs are effective at altitude up to 3,400 m 3. Acetazolamide may provide additional blood pressure benefit 3, 4, 5.